SPP1 and neoplasm: Accordingly, blocking TGF-β signaling to prevent myCAF differentiation, targeting SPP1 to disrupt CAF–tumor cell crosstalk, or inhibiting downstream ERK/MAPK signaling can restore sensitivity to ADT.